Table 2.
CYP2C19 genotype, lansoprazole treatment, and asthma control*
| Placebo |
Lansoprazole |
P Values for Pairwise Comparisons† |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| n | All | n | EM | n | PM | Plb vs. EM | Plb vs. PM | EM vs. PM | |
| ACQ‡ | |||||||||
| Baseline | 141 | 1.16 | 94 | 1.11 | 44 | 1.05 | 0.57 | 0.38 | 0.67 |
| 3 mo | 121 | 1.08 | 81 | 1.00 | 41 | 0.92 | |||
| ∆3 mo | –0.09 | –0.12 | –0.13 | 0.81 | 0.79 | 0.94 | |||
| 6 mo | 120 | 0.93 | 83 | 0.98 | 40 | 1.21 | |||
| ∆6 mo | –0.23 | –0.13 | +0.16 | 0.97 | <0.01 | 0.02 | |||
| c-ACT§ | |||||||||
| Baseline | 78 | 19.7 | 53 | 19.5 | 18 | 19.9 | 0.73 | 0.87 | 0.67 |
| 3 mo | 64 | 21.2 | 44 | 20.6 | 16 | 20.8 | 0.66 | 0.76 | 0.47 |
| ∆3 mo | 1.4 | 1.1 | 0.8 | ||||||
| 6 mo | 60 | 21.6 | 41 | 21.5 | 16 | 19.9 | 0.88 | 0.08 | 0.07 |
| ∆6 mo | 1.9 | 2.0 | 0.0 | ||||||
| ACT¶ | |||||||||
| Baseline | 60 | 18.5 | 39 | 19.0 | 25 | 19.8 | 0.54 | 0.13 | 0.40 |
| 3 mo | 51 | 20.1 | 33 | 19.7 | 23 | 20.6 | 0.31 | 0.29 | 0.92 |
| ∆3 mo | 1.6 | 0.7 | 0.8 | ||||||
| 3 mo | 55 | 20.1 | 38 | 20.5 | 22 | 20.0 | 0.89 | 0.09 | 0.10 |
| ∆6 mo | 1.6 | 1.5 | 0.2 | ||||||
| ASUI‖ | |||||||||
| Baseline | 141 | 0.82 | 94 | 0.83 | 44 | 0.83 | 0.54 | 0.83 | 0.84 |
| 3 mo | 122 | 0.85 | 81 | 0.85 | 41 | 0.86 | 0.54 | 0.82 | 0.53 |
| ∆3 mo | 0.03 | 0.02 | 0.04 | ||||||
| 6 mo | 122 | 0.88 | 84 | 0.87 | 40 | 0.84 | 0.26 | 0.17 | 0.51 |
| ∆6 mo | 0.06 | 0.04 | 0.01 | ||||||
Definition of abbreviations: ACQ = Asthma Control Questionnaire; ACT = Asthma Control Test (age, ≥12); ASUI = Asthma Symptom Utility Index; c-ACT = childhood Asthma Control Test (age, 5–11); EM = extensive metabolizer; Plb = placebo; PM = poor metabolizer.
P values for treatment effects (lansoprazole vs. placebo) from general estimating equation models including treatment status, all measurement time points, interactions with treatment status at each time point, sex, and black race. Estimates not included in table.
P values and model estimates for pairwise comparisons of placebo (all), extensive metabolizers assigned to lansoprazole, and poor metabolizers assigned to lansoprazole from general estimating equation models including lansoprazole exposure status (placebo or EM or PM), all time points, and interactions with lansoprazole exposure at each time point, sex, and black race.
Scores range from 0 to 6 with higher scores indicating worse asthma.
Scores range from 0 to 27 with lower scores indicating worse asthma.
Scores range from 5 to 25 with lower scores indicating worse asthma.
Scores range from 0 to 1, with higher values suggesting reduced symptoms.